Streetbeat News

Analyst Ratings

HUM

RBC Capital analyst Ben Hendrix maintains an Outperform rating on Humana and raises the price target from $385 to $400.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:07 pm

HPE

B of A Securities has maintained a Neutral rating on Hewlett Packard (HPE) but lowered its price target from $24 to $21, indicating a cautious outlook.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:06 pm

CNM

B of A Securities analyst Andrew Obin maintains an Underperform rating on Core & Main (NYSE:CNM) and lowers the price target from $38 to $34.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:05 pm

BMRN

JP Morgan analyst Jessica Fye maintains an Overweight rating on Biomarin Pharmaceutical and raises the price target from $111 to $120.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:05 pm

SAIA

B of A Securities analyst Ken Hoexter maintains a Buy rating on Saia and raises the price target from $443 to $460.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:03 pm

MRCY

JP Morgan analyst Seth Seifman maintains a Neutral rating on Mercury Systems (NASDAQ:MRCY) but raises the price target from $26 to $36.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:03 pm

AZN

AstraZeneca (NASDAQ:AZN) has seen significant bearish options trading activity, with 66% of trades showing bearish sentiment. The stock is currently down 3.44% at $82.8, with a projected price target of $95.0 by analysts. The options market is focusing on a price range of $79.0 to $87.5.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 4:02 pm

ANF

Abercrombie & Fitch (NYSE:ANF) has seen significant options activity, with over 11 transactions valued at $622,740. Investors are targeting a price range of $130 to $155. The stock is currently trading at $139, down 0.47%. Analysts have mixed ratings, with target prices ranging from $147 to $220.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 4:02 pm

CYTK

JP Morgan analyst Tessa Romero maintains an Overweight rating on Cytokinetics and raises the price target from $65 to $71.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:01 pm

S

SentinelOne (NYSE:S) has received mixed evaluations from 27 analysts over the past three months, with a majority leaning towards bullish sentiments. The average 12-month price target has increased by 9.03% to $28.24. Analysts have adjusted their ratings and price targets, reflecting a positive outlook on SentinelOne's market performance. Despite positive revenue growth, the company faces challenges with profitability and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 4:01 pm